ITS Interim

 
Fund Quotes for ITS Interim top ^
  • Category: Short Government
  • Morningstar Rating: 3 Stars
Sign-up for sfitx investment picks

 
News Articles for ITS Interim top ^
2014/10/13
The Charles Schwab Corporation announced today that it has scheduled an Interim Business Update for institutional investors on Monday, October 27 th .
Sign-up for Schwab Announces Its Interim Business Update investment picks
Orion Engineered Carbons S.A. (NYSE:OEC), a worldwide supplier of specialty and high-performance Carbon Black, today announced that its board of directors has declared an interim dividend of €0.67 * per common share, equivalent to a total distribution of €40 million.
Sign-up for Orion Engineered Carbons Announces Interim Cash Dividend investment picks
2014/10/30
THE HAGUE, The Netherlands , October 30, 2014 /PRNewswire/ -- The Board of Royal Dutch Shell plc ("RDS") (NYSE:RDS.A) (NYSE:RDS.B) today announced an interim dividend in respect of the third quarter of 2014 of US$0.47 per A ordinary share ("A Share") and B ordinary share ("B Share"), an increase of US$ 0.02 on the equivalent US dollar dividend for the same quarter last year.
Sign-up for Royal Dutch Shell plc Third Quarter 2014 Interim Dividend investment picks
2014/11/27
Aston Hill Asset Management Inc. Refiles Interim Financial Reports for Mutual Funds Canada NewsWire TORONTO , Nov.
Sign-up for Aston Hill Asset Management Inc. Refiles Interim Financial Reports for Mutual Funds investment picks
Analgesia in a subset of patients (50%), suggests therapeutic potential for Dex-IN in Post Op Day 1 MALVERN, Pa., Sept.
Sign-up for Recro Pharma Provides Clinical Strategy Update Following Interim Analysis for Phase IIb Clinical Trial of Dex-IN investment picks
Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) today announced updated interim results from its ongoing ARMOR2 Phase 2 clinical trial of galeterone in castration-resistant prostate cancer (CRPC) patients.
Sign-up for Tokai Pharmaceuticals Presents Updated Interim Galeterone ARMOR2 Data Showing Activity in Patients with Castration-Resistant Prostate Cancer (CRPC) Including Those Showing a Variant Form of Prostate Cancer Resistant to Hormone Therapy investment picks
2014/10/30
THE HAGUE, The Netherlands , October 30, 2014 /PRNewswire/ -- The Board of Royal Dutch Shell plc (NYSE:RDS.A) (NYSE: RDS.B) today announced the intended timetable for the 2015 quarterly interim dividends.
Sign-up for Royal Dutch Shell Plc 2015 Interim Dividend Timetable investment picks
2014/9/17
THE HAGUE, the Netherlands , September 17, 2014 /PRNewswire/ -- Shareholders were given the opportunity to choose between receiving the interim dividend of EUR 0.11 per common share in cash or in stock.
Sign-up for Aegon Determines Stock Fraction Interim Dividend and Announces to Repurchase Shares to Neutralize Stock Dividend investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1146158&ProfileId=051205&sourceType=1 HONG KONG, CHINA --
Sign-up for NetDimensions (Holdings) Limited ("NetDimensions" or the "Company" or the "Group") Interim Results for the Period Ending 30 June 2014 investment picks
2014/12/10
PARIS-- French power utility Electricite de France SA (EDF.FR) said Wednesday it will pay a 0.57 euro ($0.70) interim dividend for the fiscal year 2014.
Sign-up for EDF to Pay EUR0.57/Share Interim Dividend for Fiscal Year 2014 investment picks
CSC (NYSE: CSC), a global leader in next-generation IT services and solutions, has appointed Michael Sweeney as interim corporate controller and principal accounting officer.
Sign-up for CSC Appoints Michael Sweeney as Interim Controller investment picks
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, announced today that interim results from the first-in-human ALKA-372-001 Phase I clinical trial of RXDX-101, the company’s proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, were presented in a poster discussion session at the 2014 Congress of the European Society for Medical Oncology (ESMO) in Madrid, Spain.
Sign-up for Ignyta Announces Interim Data from RXDX-101 Phase I Clinical Trial at 2014 ESMO Congress investment picks
Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally driven diseases, today announced that updated, interim results from the company’s ongoing Phase 2 clinical trial, ARMOR2, of its lead drug candidate, galeterone, in patients with castration resistant prostate cancer (CRPC) will be presented at the 26 th EORTC-NCI-AACR Symposium on Molecular Targets in Cancer Therapeutics being held November 18-21 in Barcelona, Spain.
Sign-up for Tokai Pharmaceuticals Announces Interim Phase 2 Data on Galeterone in Patients with Advanced Prostate Cancer to be Presented at the EORTC-NCI-AACR Symposium investment picks
-- Interim Data Suggest Improved Overall Survival in Patients Treated With VB-111 in Combination With Bevacizumab (Avastin®) --
Sign-up for VBL Therapeutics to Present Interim Phase 2 Data From VB-111 in Recurrent Glioblastoma at 19th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) investment picks
HOUSTON and LONDON , Nov.
Sign-up for LyondellBasell Board Authorizes Interim Dividend investment picks
2014/12/3
Duluth Metals Granted Interim Order For Arrangement Canada NewsWire TORONTO , Dec.
Sign-up for Duluth Metals Granted Interim Order For Arrangement investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1162755&ProfileId=051205&sourceType=1 STOCKPORT, UNITED KINGDOM --
Sign-up for API Group plc ("API" or the "Group") Announces Interim Results investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

ITS Interim
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Istar Financial  |  Next: Ivanhoe Energy